1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Middle East Respiratory Syndrome (MERS) - Drugs In Development, 2022, provides an overview of the Middle East Respiratory Syndrome (MERS) (Infectious Disease) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Middle East respiratory syndrome (MERS) is a viral respiratory disease caused by a coronavirus (MERS-CoV). Symptoms include fever, cough and shortness of breath. Other symptoms include nausea, vomiting and diarrhea. Pneumonia is common, and sometimes it cause injury to organs, such as the kidneys. Treatment is aimed at relieving symptoms (joint pain and fever) with fluids and medications.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Middle East Respiratory Syndrome (MERS) - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Middle East Respiratory Syndrome (MERS) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Middle East Respiratory Syndrome (MERS) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Middle East Respiratory Syndrome (MERS) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 4, 22, 23 and 1 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 11 molecules, respectively.
Middle East Respiratory Syndrome (MERS) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Middle East Respiratory Syndrome (MERS) (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Middle East Respiratory Syndrome (MERS) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Middle East Respiratory Syndrome (MERS) (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Middle East Respiratory Syndrome (MERS) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Middle East Respiratory Syndrome (MERS) (Infectious Disease)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Middle East Respiratory Syndrome (MERS) (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Middle East Respiratory Syndrome (MERS) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Middle East Respiratory Syndrome (MERS) - Overview
- Middle East Respiratory Syndrome (MERS) - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Middle East Respiratory Syndrome (MERS) - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Middle East Respiratory Syndrome (MERS) - Companies Involved in Therapeutics Development
- Middle East Respiratory Syndrome (MERS) - Drug Profiles
- Middle East Respiratory Syndrome (MERS) - Dormant Projects
- Middle East Respiratory Syndrome (MERS) - Discontinued Products
- Middle East Respiratory Syndrome (MERS) - Product Development Milestones
- Featured News & Press Releases
- Oct 31, 2022: EpiVax joins Intravacc, CEPI on project to develop universal betacoronavirus vaccine
- Nov 04, 2021: Vaccitech announces publication of second phase 1 clinical trial results of ChAdOx1 vaccine in development for the MERS coronavirus
- Jun 14, 2021: Announcement of the effect of OBP-2011 against SARS and MERS
- Feb 23, 2021: Monoclonal antibody REGN3051 against MERS coronavirus show promise in Phase 1 NIH-sponsored trial
- Feb 23, 2021: Monoclonal antibody REGN3048 against MERS coronavirus show promise in Phase 1 NIH-sponsored trial
- Jan 27, 2020: Pulmotect’s PUL-042 shows promising pre-clinical efficacy in preventing lethal coronavirus infection
- Dec 20, 2019: New MERS vaccine clinical trial starts in Saudi Arabia
- Sep 29, 2018: Vaccitech licenses MERS rights to Oxford University: CEPI awards contract worth up to USD$19 million to Oxford University and Janssen vaccines to develop MERS, Lassa, and Nipah vaccines
- Mar 05, 2018: Hemispherx to Present Alferon N Injection at the 30th Annual ROTH Conference
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
- Number of Products under Development for Middle East Respiratory Syndrome (MERS), 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Companies, 2022 (Contd..2)
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Middle East Respiratory Syndrome (MERS) - Dormant Projects, 2022
- Middle East Respiratory Syndrome (MERS) - Discontinued Products, 2022
- Number of Products under Development for Middle East Respiratory Syndrome (MERS), 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Abcontek Inc
- Achelois Cell Therapy
- AIkido Pharma Inc
- AIM ImmunoTech Inc
- Aligos Therapeutics Inc
- Amide Technologies Inc
- Anglo Biopharma Ltd
- Autoimmune Technologies LLC
- Beroni Group Ltd
- Calder Biosciences Inc
- Chongqing Zhifei Biological Products Co Ltd
- Cidara Therapeutics Inc
- Cloud Pharmaceuticals Inc
- Cocrystal Pharma Inc
- ConserV Bioscience Ltd
- Everest Medicines Ltd
- Future Medicine Co Ltd
- Gamaleya Federal Research Center of Epidemiology and Microbiology
- Global BioLife Inc Ltd
- Greffex Inc
- Halo Therapeutics Ltd
- Immune Biosolutions Inc
- Infex Therapeutics Ltd
- Intravacc BV
- Invivyd Inc
- LegoChem Biosciences Inc
- Merck & Co Inc
- Merck KGaA
- Novavax Inc
- Oncolys BioPharma Inc
- Ostrich Pharma USA Inc
- Phelix Therapeutics LLC
- Protexase Therapeutics Inc
- Pulmotect Inc
- Regeneron Pharmaceuticals Inc
- ReVacc Biotech
- Signia Therapeutics
- Sihuan Pharmaceutical Holdings Group Ltd
- Sumagen Co Ltd
- Theravectys SA
- Tonix Pharmaceuticals Holding Corp
- Vaccitech Plc
- Valo Therapeutics Oy
- VBI Vaccines Inc
- Vir Biotechnology Inc
